10.1016/S2213-8587(19)30249-9 30 KrugerD
Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of medications primarily used for managing type 2 diabetes and, in some formulations, for chronic weight management
GLP-1 (Glucagon-Like Peptide-1) A hormone that reduces appetite, slows gastric emptying, and enhances insulin secretion
N Engl J Med 2023;389:514-526
In 2023, Juan P Frias and colleagues, in The Lancet, published the first phase two clinical trial of orforglipron, which investigated the use of a small-molecule oral GLP-1R agonist called orforglipron in type 2 diabetes, which can be taken at any time of the day without restrictions on food and water intake (Frias et al., 2023)
Higher PROM response rates can enhance clinical outcomes and support more inclusive future research